Clinical trial
A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
NCT06088472 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
- Lead sponsor
- Grit Biotechnology
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- April 21, 2021
- Completion date
- December 31, 2027
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors, adult